Welcome to our dedicated page for Respirerx Pharma news (Ticker: RSPI), a resource for investors and traders seeking the latest updates and insights on Respirerx Pharma stock.
RespireRx Pharmaceuticals Inc. (RSPI) generates news primarily through research, clinical development, regulatory and capital markets activities related to its neuromodulator and pharmaceutical cannabinoid programs. Through the RespireRx Group, which includes EndeavourRx LLC and ResolutionRx Ltd, the company reports progress on drug candidates targeting epilepsy, pain, attention deficit hyperactivity disorder (ADHD), recovery from spinal cord injury (SCI), certain neurological orphan diseases and obstructive sleep apnea (OSA).
News updates often highlight preclinical and translational findings for the company’s lead compounds. For example, RespireRx has reported peer-reviewed publications demonstrating that its AMPAkine CX1739 improved bladder function in rodent models of spinal cord injury and that KRM-II-81, its lead GABAkine, suppressed epileptiform activity in human brain tissue slices from a pharmaco-resistant epilepsy patient. Additional releases describe KRM-II-81’s advancement within the NIH HEAL Initiative Preclinical Screening Platform for Pain, where it has shown anti-pain effects in animal models at doses with minimal or no detectable side effects.
Investors and observers can also find announcements about external funding and collaborations, such as a Department of Defense translational research award to Shirley Ryan AbilityLab for a Phase 2A/2B clinical trial of CX1739 in SCI patients and an NIH/NINDS Small Business Innovation Research (SBIR) grant to support IND-enabling work for KRM-II-81 in epilepsy. Company communications further cover strategic steps at ResolutionRx Ltd to advance a new dronabinol formulation for OSA, including use of the Australian R&D Tax Incentive and plans for stock exchange listings.
Regulatory and corporate developments are another key theme in RSPI news. RespireRx has issued releases about SEC correspondence, the Section 12(j) order revoking registration of its securities, and its stated intention to pursue future Form 10 registration. Capital-raising initiatives, including a Regulation D, Rule 506(c) private placement across RespireRx, EndeavourRx and ResolutionRx, are also described. For ongoing context on RSPI, readers can review this news stream for updates on clinical plans, grant awards, licensing agreements, governance changes and the company’s responses to regulatory actions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) has entered a material transfer agreement with University College London (UCL) to collaborate on research involving CX1739, its lead AMPAkine, aimed at treating GRIA disorders. These rare genetic diseases affect AMPA receptor functioning, impacting learning and memory. Dr. Ian Coombs is leading efforts to identify specific genetic variants in children with GRIA Disorder to tailor treatments effectively. Positive effects of CX1739 have been noted in animal models, and the study seeks to confirm its therapeutic potential in humans.
RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) announced the publication of four studies detailing the pharmacological effects of new structural analogs of its lead compound, KRM-II-81. These analogs enhance GABAergic neurotransmission and show promise as anti-seizure agents without sedation. The studies demonstrated that KRM-II-81 effectively addresses epilepsy and pain without developing tolerance. Notably, the analog MP-III-024 proved effective in tremor models related to Parkinson's Disease. The company's focus on advancing KRM-II-81's development aims to facilitate upcoming human studies, potentially leading to breakthrough treatments for conditions lacking adequate therapies.
RespireRx Pharmaceuticals Inc. (OTC: RSPI) announced on March 22, 2023, the appointment of Joseph Siegelbaum as an independent director of its Board. Siegelbaum, previously a partner at Goodwin Procter LLP, brings extensive legal experience and a strong background in nonprofit leadership. Executive Chairman Dr. Lippa expressed confidence that Siegelbaum's expertise will enhance the Board's effectiveness. RespireRx focuses on developing treatments for psychiatric and neurological disorders, including a promising pipeline targeting obstructive sleep apnea and ADHD. The company continues to advance its innovative drug platforms with no approved treatments currently available for these conditions.
On March 1, 2023, ResolutionRx, a wholly-owned subsidiary of RespireRx Pharmaceuticals (OTC: RSPI), announced a services agreement with iNGENu CRO Pty Ltd for clinical research focused on a proprietary dronabinol formulation aimed at treating obstructive sleep apnea and anorexia. The agreement requires an initial deposit of US$50,000, part of a total R&D budget of approximately US$16.5 million. Notable developments include the formation of ResolutionRx, entry into financing arrangements with Radium Capital for R&D tax credits, and plans for further research activities in Australia. The company aims to commence clinical studies pending adequate financing and regulatory approvals.
RespireRx Pharmaceuticals (OTC: RSPI) announced a Letter of Intent and Term Sheet between its wholly-owned subsidiary ResolutionRx Ltd and Radium Capital on January 27, 2023. This partnership aims to establish financing arrangements to access research and development tax credits in Australia. The R&D Tax Incentive could provide ResolutionRx with a 43.5% tax refund to support its efforts in commercializing dronabinol for obstructive sleep apnea treatment. The total budget for this initiative is approximately $16.5 million, with a significant portion expected to qualify for the R&D tax refund.
RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) announced a significant amendment to its Exclusive License Agreement with the University of Illinois. The changes, effective December 15, 2022, include the elimination of $100,000 annual payments and a reduction of $200,000 in unpaid dues for 2021 and 2022. Future obligations are adjusted, with a $10,000 payment due after the first patient doses in Phase II, among other modifications. The agreement extension includes a 4% royalty on net sales for up to eight years post-patent expiration, increasing minimum payments to $350,000 upon FDA approval. This aims to streamline financial liabilities and enhance drug development focus.